H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro

15 May 2021: Database Analysis

Min Luo ^1ABCE , Yao Xiong ^2BCE , Yan Lin ^1CD , Rong Liang ^1CD , Yongqiang Li ^1D , Lianying Ge ^3ADE*

DOI: 10.12659/MSM.930215

Med Sci Monit 2021; 27:e930215

Table 1 Summary of the clinicopathological characteristics of patients with hepatocellular carcinoma and HHLA2 protein expression.

Characteristic		Number of patients	HHLA2 expression	P vaule
Characteristic		Number of patients	χ̄±s	P vaule
Gender	Male	48	0.910±0.280	0.058
Gender	Female	7	0.700±0.133	0.058
Age (years)	≤55	23	0.940±0.229	0.216
Age (years)	>55	32	0.846±0.299	0.216
Smoking	No	35	0.857±0.278	0.348
Smoking	Yes	20	0.930±0.269	0.348
Drinking	No	42	0.860±0.276	0.261
Drinking	Yes	13	0.956±0.268	0.261
BCLC stage	A	33	0.726±0.206	^**
	B	7	1.006±0.233
	C	15	1.137±0.126
Differentiation	High and moderate	34	0.811±0.272	0.008^**
Differentiation	Poor	21	1.008±0.237	0.008^**
AFP (ng/ml)	≤200	32	0.855±0.246	0.237
AFP (ng/ml)	>200	23	0.940±0.278	0.237
Tumour capsular	No	45	0.889±0.288	0.733
Tumour capsular	Yes	10	0.856±0.215	0.733
Tumor size (cm)	≤5	21	0.839±0.280	0.355
Tumor size (cm)	>5	34	0.910±0.272	0.355
HBV infection	No	16	0.842±0.217	0.481
HBV infection	Yes	39	0.900±0.296	0.481
Liver cirrhosis	No	32	0.828±0.308	0.078
Liver cirrhosis	Yes	23	0.960±0.201	0.078
Adjacent structures invasion	No	45	0.837±0.274	0.007^**
Adjacent structures invasion	Yes	10	1.090±0.166	0.007^**
PVTT	No	47	0.855±0.277	0.060
PVTT	Yes	8	1.051±0.197	0.060
Lymph node metastasis	No	49	0.875±0.286	0.520
Lymph node metastasis	Yes	6	0.952±0.146	0.520
BCLC – Barcelona Clinic Liver Cancer; HBV – hepatitis B virus; PVTT – portal vein tumor thrombus; ^**